Pharmacologic administration of interleukin-2: Inducing a systemic autophagic syndrome

Annals of the New York Academy of Sciences

Volumn 1182, Issue , 2009, Pages 14-27

  Chavez, Antonio Romo De Vivar ^a,b,d   Buchser, William ^a   Basse, Per H ^a,c   Liang, Xiaoyan ^a,b,d   Appleman, Leonard J ^a,b   Maranchie, Jodi K ^a,c   Zeh, Herbert ^a,b   De Vera, Michael E ^a,b,d   Lotze, Michael T ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Department of Surgery ^*

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Autophagy; Biologic therapy; Cancer; Chloroquine; HMGB1; Interleuken 2

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CHLOROQUINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ETHYLPYRUVATE; HIGH MOBILITY GROUP B1 PROTEIN; INTERFERON; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EFFECTOR CELL; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOMODULATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PROGNOSIS; REGULATORY T LYMPHOCYTE; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT;

EID: 73849109835     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05160.x     Document Type: Conference Paper

References (56)

1. Rosenberg, S.A., J.C. Yang, S.L. Topalian, et al. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using highdose bolus interleukin 2. JAMA 271: 907-913.
2. Schwartzentruber, D.J. et al. 2009. A phase III multiinstitutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by highdose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J. Clin. Onc. 27:185, part 2/2, 807S.
3. Lotze, M.T., L.W. Frana, S.O. Sharrow, et al. 1985. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol. 134: 157-166.
4. Lotze, M.T., Y.L. Matory, S.E. Ettinghausen, et al. 1985. In vivo administration of purified human interleukin II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135: 2865-2875.
5. Lotze, M.T., R.J. Robb, S.O. Sharrow, et al. 1984. Systemic administration of interleukin-2 in humans. J. Biol. Response Mod. 3: 475-482.
6. Gordon, J. & L.D. Maclean. 1965. A lymphocytestimulating factor produced in vitro. Nature 208: 795-796.
7. Granucci, F., I. Zanoni, N. Pavelka, et al. 2004. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J. Exp. Med. 200: 287-295.
8. Cousens, L.P., J.S. Orange & C.A. Biron. 1995. Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. J. Immunol. 155: 5690-5699.
9. Schmidt, R.E., T. Hercend, D.A. Fox, et al. 1985. The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. J. Immunol. 135: 672-678. (Pubitemid 15012444)
10. Klempner, M.S., R. Noring, J.W. Mier & M.B. Atkins. 1990. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N. Engl. J. Med. 322: 959-965.
11. Phuoc, N.B., H. Ehara, T. Gotoh, et al. 2008. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol. Rep. 20: 525-530.
12. Romo de Vivar Chavez, A., M.E. de Vera, X. Liang & M.T. Lotze. 2009. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Med. Oncol. 26(Suppl 1): 3-12.
13. Gemlo, B.T., M.A. Palladino, Jr., H.S. Jaffe, et al. 1988. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 48: 5864-5867.
14. Atkins, M.B., B. Redman, J. Mier, et al. 2001. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin. Cancer Res. 7: 486-492.
15. Du Bois, J.S., E.G. Trehu, J.W. Mier, et al. 1997. Randomized placebo-controlled clinical trial of highdose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J. Clin. Oncol. 15: 1052-1062.
16. McDermott, D.F., E.G. Trehu, J.W.Mier, et al. 1998. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin. Cancer Res. 4: 1203-1213.
17. West, W.H., K.W. Tauer, J.R. Yannelli, et al. 1987. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316: 898-905.
18. DeVita,V.T., S. Hellman&S.A.Rosenberg. 1995. Biologic Therapy of Cancer, 2nd edn. Lippincott. Philadelphia.
19. Bone, R.C., R.A. Balk, F.B. Cerra, et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
20. Deans, K.J., M. Haley, C. Natanson, et al. 2005. Novel therapies for sepsis: A review. J. Trauma. 58: 867-874.
21. Carson,W.E., H. Yu, J. Dierksheide, et al. 1999. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J. Immunol. 162: 4943-4951.
22. Bohrer,H., F. Qiu, T. Zimmermann, et al. 1997. Role of NFkappaB in the mortality of sepsis. J. Clin. Invest. 100: 972-985.
23. Rangel-Frausto, M.S., D. Pittet, M. Costigan, et al. 1995. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273: 117-123.
24. Hotte, S., T.Waldron, C. Canil & E.Winquist. 2007. Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: A systematic review and practice guideline. Can. Urol. Assoc. J. 1: 27-38.
25. Kragel, A.H., W.D. Travis, L. Feinberg, et al. 1990. Pathologic findings associated with interleukin-2-based immunotherapy for cancer: A postmortem study of 19 patients. Hum. Pathol. 21: 493-502.
26. Boya, P., R.A. Gonzalez-Polo, N. Casares, et al. 2005. Inhibition of macroautophagy triggers apoptosis. Mol. Cell Biol. 25: 1025-1040.
27. Matsui, Y., H. Takagi, X. Qu, et al. 2007. Distinct roles of autophagy in the heart during ischemia and reperfusion: Roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ. Res. 100: 914-922.
28. Mier, J.W., C.A. Dinarello, M.B. Atkins, et al. 1987. Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells. J. Immunol. 139: 1268-1272.
29. Levine, B. 2007. Cell biology: Autophagy and cancer. Nature 446: 745-747.
30. Maiuri, M.C., E.Zalckvar, A. Kimchi&G. Kroemer. 2007. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 8: 741-752.
31. Amaravadi, R.K., D. Yu, J.J. Lum, et al. 2007. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. 117: 326-336.
32. Zheng, Y., Y.L. Zhao, X. Deng, et al. 2009. Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis. Cancer Invest. 27: 286-292.
33. Maclean, K.H., F.C. Dorsey, J.L. Cleveland & M.B. Kastan. 2008. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J. Clin. Invest. 118: 79-88.
34. Dang, C.V. 2008. Antimalarial therapy prevents Myc-induced lymphoma. J. Clin. Invest. 118: 15-17.
35. Bellodi, C., M.R. Lidonnici, A. Hamilton, et al. 2009. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J. Clin. Invest. 119: 1109-1123.
36. Ding, W.X., H.M. Ni, W. Gao, et al. 2009. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol. Cancer Ther. 8: 2036-2045.
37. Apetoh, L., F. Ghiringhelli, A. Tesniere, et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13: 1050-1059.
38. Lotze, M.T., H.J. Zeh, A. Rubartelli, et al. 2007. The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 220: 60-81.
39. Daolin Tang, R.K., P. Loughran, A.M. Farkas, et al. 2008. The damage associated molecular pattern molecule (DAMP) high mobility group box protein-1 (HMGB1) is an activator of autophagy. J. Leuk. Biol. 84: A19-20. (Abstract).
40. Liang, X., A.Romo-Vivar,N.E. Schapiro, et al. 2009. Ethyl pyruvate administration inhibits hepatic tumor growth. J. Leukoc. Biol. 2009 Jul 7.
41. Thorburn, J., H. Horita, J. Redzic, et al. 2009. Autophagy regulates selectiveHMGB1 release in tumor cells that are destined to die. Cell Death Differ. 16: 175-183.
42. Atkins, M., M. Regan, D. McDermott, et al. 2005. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11: 3714-3721.
43. Bui, M.H., D. Seligson, K.R. Han, et al. 2003. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9: 802-811.
44. Miyake, H., I. Sakai, M. Muramaki, et al. 2009. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: Expression patterns of potential molecular markers in radical nephrectomy specimens. Int. J. Urol. 2009 Apr 7.
45. Maruyama, R., K. Yamana, T. Itoi, et al. 2006. Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br. J. Cancer 95: 1244-1249.
46. Yap, T.A. & T.G. Eisen. 2006. Adjuvant therapy of renal cell carcinoma. Clin. Genitourin. Cancer 5: 120-130.
47. Dorval, T., W.H. Fridman, C. Mathiot & P. Pouillart. 1992. Interleukin-2 therapy for metastatic uveal melanoma. Eur. J. Cancer 28A: 2087.
48. Keilholz, U., C. Scheibenbogen, M. Brado, et al. 1994. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur. J. Cancer 30A: 103-105.
49. Phan, G.Q., P. Attia, S.M. Steinberg, et al. 2001. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19: 3477-3482.
50. Casamassima, A., M. Picciariello,M.Quaranta, et al. 2005. C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J. Urol. 173: 52-55.
51. Royal, R.E., S.M. Steinberg, R.S.Krouse, et al. 1996. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J. Sci. Am. 2: 91-98.
52. Sabatino, M., S. Kim-Schulze, M.C. Panelli, et al. 2009. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol. 27: 2645-2652.
53. Tartour, E., J.Y. Blay, T. Dorval, et al. 1996. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multiinstitutional study. J. Clin. Oncol. 14: 1697-1703.
54. Bonfanti, A., P. Lissoni, R. Bucovec, et al. 2000. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer. Int. J. Biol. Markers 15: 161-164.
55. Cesana, G.C., G. DeRaffele, S. Cohen, et al. 2006. Characterization ofCD4+CD25+regulatoryTcells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24: 1169-1177.
56. Abrams, D. et al. 2009. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361(16): 1548-1559.